Shares of Zydus Lifesciences Ltd are trading flat after touching a day’s high of Rs 916.45 on 16th February, despite the company announcing that it had received final approval from the United States Food and Drug Administration (USFDA) for Ammonium Lactate Cream, 12%.

Ammonium Lactate Cream, 12% is a prescription topical medicine. It is used to treat dry, scaly skin (xerosis) and a genetic skin condition called ichthyosis vulgaris.

It helps increase skin hydration and, as an alpha-hydroxy acid, reduces itching, softens the skin, and improves scaling.

The product will be manufactured at the group’s topical facility in Changodar, Ahmedabad. Additionally, it will be marketed in the US by Viona Pharmaceuticals Inc.

According to IQVIA MAT December 2025 data, the cream recorded annual US sales of $15 million.

With this approval, the group now has 430 approvals. It has filed 505 ANDAs since it began filings in FY 2003-04.

At 12:32 PM, shares of Zydus Lifesciences were trading 0.32% higher at Rs 907.55 on NSE.

Ready to invest like a pro? Tradz by EquityPandit equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz app and gain access to daily stock lists and insightful market analysis and much more!